目的：系统评价环喷托酯和阿托品应用于近视儿童验光前的睫状肌麻痹效应和安全性。方法：在PubMed、EMBASE、Web of Science、The Cochrane Library、中国知网(CNKI)、万方数据库中检索自建库至2020-04发表的关于比较环喷托酯与阿托品用于近视儿童睫状肌麻痹效果的相关文献。对于筛选出来的文献，经资料提取和质量评价后，采用RevMan5.3软件进行Meta分析。结果：本研究最终纳入9篇文献，其中使用阿托品者588眼，使用环喷托酯者592眼。Meta分析结果显示，近视儿童验光前使用环喷托酯和阿托品进行睫状肌麻痹后屈光度[WMD=-0.01，95%CI(-0.30，0.27)，P=0.93]和残余调节力[WMD=0.22， 95%CI(-0.13，0.58)，P=0.22]均无差异，但环喷托酯不良反应发生率较低，更安全。结论：环喷托酯与阿托品对近视儿童的睫状肌麻痹作用相当，且安全性较高，可以替代阿托品对近视儿童在验光前使用。

AIM: To systematically evaluate the effect and safety of cyclopentolate and atropine on ciliary muscle paralysis before optometry in myopic children. METHODS: Relevant references published before April 2020, which concerned about cyclopentolate compared with atropine for ciliary muscle palsy in children with myopia, were obtained by searching PubMed, EMBASE, Web of Science, The Cochrane Library, CNKI and WanFang Database. For the selected studies, after data extraction and methodological quality evaluation of the included study, RevMan5.3 software was used for Meta-analysis. RESULTS: Nine articles were finally included, containing 588 eyes using atropine and 592 eyes using cyclopentolate. Meta-analysis results indicated: comparing of cyclopentolate and atropine for cycloplegia in children with myopia before optometry, the diopter difference between the two is WMD: -0.01, 95%CI(-0.30, 0.27), P=0.93; the difference in residual accommodation power between the two is WMD: 0.22, 95%CI(-0.13, 0.58), P=0.22. In addition, the cyclopentolate is safer and has a lower incidence of adverse reactions.CONCLUSION: Compared with atropine, cyclopentolate has equivalent effects on ciliary muscle paralysis in myopic children, and has higher security. Cyclopentolate could replace atropine for myopic children before optometry.

西安市科技计划项目[No.20YXXJ008(6)]